2023 Alzheimer's disease facts and figures
- PMID: 36918389
- DOI: 10.1002/alz.13016
2023 Alzheimer's disease facts and figures
Abstract
This article describes the public health impact of Alzheimer's disease, including prevalence and incidence, mortality and morbidity, use and costs of care, and the overall impact on family caregivers, the dementia workforce and society. The Special Report examines the patient journey from awareness of cognitive changes to potential treatment with drugs that change the underlying biology of Alzheimer's. An estimated 6.7 million Americans age 65 and older are living with Alzheimer's dementia today. This number could grow to 13.8 million by 2060 barring the development of medical breakthroughs to prevent, slow or cure AD. Official death certificates recorded 121,499 deaths from AD in 2019, and Alzheimer's disease was officially listed as the sixth-leading cause of death in the United States. In 2020 and 2021, when COVID-19 entered the ranks of the top ten causes of death, Alzheimer's was the seventh-leading cause of death. Alzheimer's remains the fifth-leading cause of death among Americans age 65 and older. Between 2000 and 2019, deaths from stroke, heart disease and HIV decreased, whereas reported deaths from AD increased more than 145%. This trajectory of deaths from AD was likely exacerbated by the COVID-19 pandemic in 2020 and 2021. More than 11 million family members and other unpaid caregivers provided an estimated 18 billion hours of care to people with Alzheimer's or other dementias in 2022. These figures reflect a decline in the number of caregivers compared with a decade earlier, as well as an increase in the amount of care provided by each remaining caregiver. Unpaid dementia caregiving was valued at $339.5 billion in 2022. Its costs, however, extend to family caregivers' increased risk for emotional distress and negative mental and physical health outcomes - costs that have been aggravated by COVID-19. Members of the paid health care workforce are involved in diagnosing, treating and caring for people with dementia. In recent years, however, a shortage of such workers has developed in the United States. This shortage - brought about, in part, by COVID-19 - has occurred at a time when more members of the dementia care workforce are needed. Therefore, programs will be needed to attract workers and better train health care teams. Average per-person Medicare payments for services to beneficiaries age 65 and older with AD or other dementias are almost three times as great as payments for beneficiaries without these conditions, and Medicaid payments are more than 22 times as great. Total payments in 2023 for health care, long-term care and hospice services for people age 65 and older with dementia are estimated to be $345 billion. The Special Report examines whether there will be sufficient numbers of physician specialists to provide Alzheimer's care and treatment now that two drugs are available that change the underlying biology of Alzheimer's disease.
Keywords: Alzheimer's dementia; Alzheimer's disease; Biomarkers; COVID-19; Caregivers; Dementia; Dementia workforce; Diagnostic criteria; Family caregiver; Health care costs; Health care expenditures; Health care professional; Incidence; Long-term care costs; MCI due to Alzheimer's disease; Medicaid spending; Medicare spending; Mild cognitive impairment; Morbidity; Mortality; Prevalence; Primary care physician; Risk factors.
© 2023 the Alzheimer's Association.
Similar articles
-
2022 Alzheimer's disease facts and figures.Alzheimers Dement. 2022 Apr;18(4):700-789. doi: 10.1002/alz.12638. Epub 2022 Mar 14. Alzheimers Dement. 2022. PMID: 35289055
-
2024 Alzheimer's disease facts and figures.Alzheimers Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809. Epub 2024 Apr 30. Alzheimers Dement. 2024. PMID: 38689398 Free PMC article.
-
2021 Alzheimer's disease facts and figures.Alzheimers Dement. 2021 Mar;17(3):327-406. doi: 10.1002/alz.12328. Epub 2021 Mar 23. Alzheimers Dement. 2021. PMID: 33756057
-
Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet].Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172. PMID: 28876770 Free Books & Documents. Review.
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. PMID: 24354019 Free Books & Documents. Review.
Cited by
-
Explainable AI and transformer models: Unraveling the nutritional influences on Alzheimer's disease mortality.Smart Health (Amst). 2024 Jun;32:100478. doi: 10.1016/j.smhl.2024.100478. Epub 2024 Mar 20. Smart Health (Amst). 2024. PMID: 39087069 Free PMC article.
-
Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer's disease.Alzheimers Res Ther. 2024 Aug 1;16(1):173. doi: 10.1186/s13195-024-01537-1. Alzheimers Res Ther. 2024. PMID: 39085976 Free PMC article.
-
BPSD reconsidered: diagnostic considerations to preserve personhood in persons with dementia.Front Dement. 2023 Nov 22;2:1272400. doi: 10.3389/frdem.2023.1272400. eCollection 2023. Front Dement. 2023. PMID: 39081991 Free PMC article. Review.
-
Can a translational science approach change the dementia narrative in medical education?Front Dement. 2023 Nov 24;2:1288817. doi: 10.3389/frdem.2023.1288817. eCollection 2023. Front Dement. 2023. PMID: 39081977 Free PMC article. No abstract available.
-
Introduction to Large Language Models (LLMs) for dementia care and research.Front Dement. 2024 May 14;3:1385303. doi: 10.3389/frdem.2024.1385303. eCollection 2024. Front Dement. 2024. PMID: 39081594 Free PMC article.
References
REFERENCES
-
- Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid's deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367.
-
- Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11(2):1048-1056.
-
- Jack CR, Lowe VJ, Weigand SD, et al. Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132:1355-1365.
-
- Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804.
-
- Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol. 2018;17(3):241-250.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical